RNAZTransCode TherapeuticsRunning, no new patients
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
Advanced Solid Tumor
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Sep 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 1/2
- Patients
- 16 (final count)
- Started
- Sep 5, 2024
- Main results expected
- Sep 30, 2025
- Fully finished
- Feb 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Escalation - Adverse Events
Measured over: Throughout study treatment for 18 subjects, for average of 3 months and post treatment for survival follow-up through study completion, an average of 1 year
Dose Escalation - Overall Response Rate (ORR)
Measured over: Throughout study treatment for 18 subjects, for average of 3 months and post treatment for survival follow-up through study completion, an average of 1 year
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-09-30, no fading
Raw record changes
- none yet
Trial ID NCT06260774 · record last updated 2025-10-02 · checked 2026-11-09 15:47 UTC